Core Viewpoint - The strategic cooperation between Weisheng Pharmaceutical and Anke Bio aims to promote the long-acting growth hormone product, Longpei Growth Hormone, in the Chinese market, leveraging Anke's extensive experience and sales network in the biopharmaceutical sector [1][2]. Group 1: Partnership Details - Weisheng Pharmaceutical has signed a strategic cooperation framework agreement with Anke Bio, granting Anke exclusive promotion rights for Longpei Growth Hormone in specific regions of China [1]. - The collaboration will focus on the commercialization of Longpei Growth Hormone and explore broader cooperation on other target products, including localized production and marketing [1]. - Anke Bio has over 30 years of experience in biopharmaceuticals and a well-established sales network, which will facilitate Weisheng's market entry [1]. Group 2: Product Information - Longpei Growth Hormone is a new long-acting growth hormone designed to treat pediatric growth hormone deficiency (PGHD) and is expected to provide new treatment options for affected children [1]. - The product has already been approved for sale in the United States and Europe, with expectations for approval in China by 2025 and plans for localized commercial production by 2028 [1]. Group 3: Strategic Importance - Anke Bio's chairman highlighted that the collaboration will enhance their commercial layout in the pediatric growth field and redefine the growth hormone market [2]. - Weisheng's CEO emphasized the synergy between their innovative research and Anke's established sales channels, aiming to accelerate the product's market introduction and benefit a wide patient population [2].